US FDA Approves Regeneron’s Cholesterol Drug in Children
This Wednesday, Regeneron Pharmaceuticals Inc announced that the United States Food and Drug Administration (US FDA) has approved its drug Evkeeza for use in children with homozygous familial hypercholesterolemia (HoFH), between 5-11 years of age.
HoFH – an inherited condition, is a rare disorder that causes high low-density lipoprotein (LDL) cholesterol levels and predisposes to premature cardiovascular diseases. In 2021, this drug gained approval as an additional treatment with other lipid-lowering therapies for children with HoFH, aged 12 years and above.
More FAQs by
Recent FAQs
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article